REG - ABCAM Plc - Director/PDMR Shareholding

 
For best results when printing this announcement, please click on the link below:
http://pdf.reuters.com/Regnews/regnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20100505:nRSE3726La
RNS Number : 3726L
ABCAM Plc
05 May 2010 
 
Abcam plc ("Abcam" or "the Company") 
 
Director Dealings 
 
Cambridge, UK: Abcam plc (AIM: ABC), the rapidly growing bioscience company that markets antibodies via its own online
catalogue, announces that it was notified on 5 May 2010 that Prof. Tony Kouzarides, a non-executive director of the
Company, sold 5,000 ordinary shares of 1 pence each in the Company on 5 May 2010 at a price of 1187p per ordinary share.
Following this transaction Prof. Kouzarides has an interest in 80,244 ordinary shares of 1 pence each in the Company
representing approximately 0.22% of the Company's issued share capital. 
 
 Abcam                                             + 44 (0) 1223 696000   
 Jonathan Milner, Chief Executive Officer                                 
 Jeffrey Iliffe, Chief Financial Officer                                  
                                                                          
 Numis Securities                                  + 44 (0) 20 7260 1000  
 Michael Meade / Nick Westlake, Nominated Adviser                         
 James Black, Corporate Broking                                           
                                                                          
 Buchanan Communications                           + 44 (0) 20 7466 5000  
 Mark Court / Stasa Filiplic                                              
 
 
Notes for editors: 
 
About Abcam plc 
 
Abcam is a producer and distributor of research-grade antibodies headquartered in Cambridge, United Kingdom, with
subsidiaries in Cambridge, Massachusetts, Tokyo and Hong Kong. Abcam was admitted to AIM in November 2005 and trades under
the ticker symbol ABC. The Company produces and distributes its own and third-party produced antibodies and related
products to academic and commercial users throughout the world. Product ordering is available through the Company's website
www.abcam.com, where customers are also able to access up-to-date and detailed technical product data sheets. All the
antibodies are sold under the Abcam brand name. Abcam's mission is to develop the largest catalogue of the best antibodies
in the world, with the vision of becoming a global leader in the wider protein detection and regulation markets. Abcam now
has a rapidly growing online catalogue and as at 31 December 2009 it contained 57,960 products, most of which are
antibodies, from over 250 suppliers. Abcam employs 250 staff in its four operating companies. 
 
This information is provided by RNS
The company news service from the London Stock Exchange
back to RNS news